slu pp 332 and retatrutide together SLU-PP-332 (50mg x 60 tabs = 3,000,000mcg) SLU-PP-332 – Peptidnova
Description
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Diabetes (2012) 61:21728
In the SURMOUNT-1 trial, Tirzepatide produced average weight reductions of 15.0%, 19.5%, and 20.9% at weekly doses of 5 mg, 10 mg, and 15 mg respectively, over 72 weeks (Jastreboff et al., NEJM 2022
So this was your reporting
Understanding these factors is crucial for the identification and treatment of high-risk individuals undergoing treatment with GLP-1RAs
Additionally, the weight loss itself may be problematic in some sense
